Last reviewed · How we verify
18F-AV-1451
18F-AV-1451 is a Small molecule drug developed by Mayo Clinic. It is currently in Phase 2 development. Also known as: formally known as 18F-T807, 7-(6-[18F]fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole, [F-18]T807, [18F]AV-1451.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | 18F-AV-1451 |
|---|---|
| Also known as | formally known as 18F-T807, 7-(6-[18F]fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole, [F-18]T807, [18F]AV-1451, AV-1451 |
| Sponsor | Mayo Clinic |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Elevated blood pressure
- claustrophobia
- diarrhoea
- Black dot in visual field
- Muscle soreness in injection arm
- Neck rash
- Diarrhea, drowsiness, nausea
- headache
- musculoskeletal discomfort
Key clinical trials
- Alzheimer's Disease Neuroimaging Initiative 4
- Longitudinal Early-onset Alzheimer's Disease Study Protocol
- UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy (PHASE1)
- Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study
- Tau PET Outcomes With Anti-amyloid Immunotherapies (PHASE2)
- Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease (PHASE1)
- Tau PET Imaging in the NACC Study Cohort
- PET Tau - Neurodegenerative Disease Imaging (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-AV-1451 CI brief — competitive landscape report
- 18F-AV-1451 updates RSS · CI watch RSS
- Mayo Clinic portfolio CI
Frequently asked questions about 18F-AV-1451
What is 18F-AV-1451?
Who makes 18F-AV-1451?
Is 18F-AV-1451 also known as anything else?
What development phase is 18F-AV-1451 in?
What are the side effects of 18F-AV-1451?
Related
- Manufacturer: Mayo Clinic — full pipeline
- Also known as: formally known as 18F-T807, 7-(6-[18F]fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole, [F-18]T807, [18F]AV-1451, AV-1451
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing